1.22
-0.06(-4.69%)
Currency In USD
Previous Close | 1.28 |
Open | 1.28 |
Day High | 1.32 |
Day Low | 1.17 |
52-Week High | 5.12 |
52-Week Low | 1.17 |
Volume | 158,339 |
Average Volume | 74,948 |
Market Cap | 51.85M |
PE | -2.84 |
EPS | -0.43 |
Moving Average 50 Days | 2.03 |
Moving Average 200 Days | 2.61 |
Change | -0.06 |
If you invested $1000 in Elutia Inc. (ELUT) since IPO date, it would be worth $84.14 as of September 15, 2025 at a share price of $1.22. Whereas If you bought $1000 worth of Elutia Inc. (ELUT) shares 3 years ago, it would be worth $168.28 as of September 15, 2025 at a share price of $1.22.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Elutia Announces Sale of BioEnvelope Business to Boston Scientific Corporation for $88 Million
GlobeNewswire Inc.
Sep 09, 2025 12:30 PM GMT
- Transaction affirms the strength of Elutia’s proprietary drug-eluting biologics platform and fully funds advancement of NXT-41 in breast reconstruction - - Company to provide update at the H.C. Wainwright 27th Annual Global Investment Conference on
Elutia Selected to Exhibit EluPro™ Antibiotic Eluting BioEnvelope at Vizient Innovative Technology Exchange
GlobeNewswire Inc.
Sep 04, 2025 12:00 PM GMT
GAITHERSBURG, Md., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it has been selected to exhibit the EluPro™ Antibiotic-Eluting BioE
Elutia to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025
GlobeNewswire Inc.
Jul 31, 2025 8:05 PM GMT
GAITHERSBURG, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its second quarter 2025 financial results after mark